Working… Menu

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03837353
Recruitment Status : Recruiting
First Posted : February 12, 2019
Last Update Posted : March 23, 2021
Leap Therapeutics, Inc.
Information provided by (Responsible Party):
NYU Langone Health